Confronto

Amycretin vs. VK2735

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

Peso molecolare

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Amycretin	VK2735
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Amycretin and VK2735?: Amycretin is classified as "Metabolico", while VK2735 is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or VK2735?: The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and VK2735 in Germany and the United States?: Germania: Amycretin — Non approvato, VK2735 — Non approvato. Stati Uniti: Amycretin — Non approvato, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

VK2735

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Amycretin and VK2735?

Amycretin is classified as "Metabolico", while VK2735 is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or VK2735?

The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and VK2735 in Germany and the United States?

Germania: Amycretin — Non approvato, VK2735 — Non approvato. Stati Uniti: Amycretin — Non approvato, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.